INTRODUCTION:
dvertising is a key element of marketing strategy [[[and advertising messages consist of acombination of information and persuasion 1 . Advertising in brochure form is a common "educational" gif supplied by pharmaceutical company representatives (PCRs) during their promotional visits and it can provide written reinforcement of any verbal message provided by PCRs. In Libya, a concurrent study foundthat79% of surveyed respondents reported they were supplied promotional printed material by PCRs during promotional visits 2 and 94% of the respondents reported that new information about pharmaceutical products was the main benefit they received from their interactions with PCRs 3 .A brochure is apassive, convenient source of education and requires little effort to access. It may be tailored to a doctor's request. It provides a summaryof the scientific literature with graphs and references to support its advertising claims. It conveys information to readers in an attractive way since it is designed[ to be persuasive, [ describes how attitudes can be influenced by persuasive messages. It assumes that there are two routes through which persuasive messages are processed: the central route is depicted by thoughtful consideration and evaluation of the arguments and that attitude shaped from this message is predominantly cognitive. However, in the peripheral route, the reader who is unable to fully process all information received or who is unwilling to engage in a deeper thought process can be persuaded by using 'heuristic' means, such as visual image, tunes, colours,[ and celebrity endorsements. Pharmaceutical company interaction has been reported as one of the primary influenceon doctors'prescribing decisions 7, 8 . Pharmaceutical companies claim that promotion provides scientific and educational information to the doctors and ensures that patients receive the products they need in the correct dosage with adequate information about the usage of the products in order to ensure a positive health outcome for the patient 9 . Rational responsible prescribing assumes that a medical professional balance the positive and negative features of each product and consider all the alternatives. Pharmaceutical promotional activities are regulated by several international and national guidelines. The World Health Organisation (WHO) and the International Federation of Pharmaceutical Manufacturers Association (IF-PMA) establish the standards for ethical promotion of medicines by pharmaceutical companies. They emphasize that promotional practices must be reliable, accurate, truthful and not misleading. In the USA, the Food and Drug Administration (FDA) regulations require that all promotional printed material be accurate, balanced and consistent with the approved therapeutic claims 10 .However, in many countries, pharmaceutical companies do not always comply with these standards. Existing research demonstrates that pharmaceutical drug brochures can provide insufficient 11, 12 and unsubstantiated information 11, 13 as well as vague and misleading claims 11,12, 14, 16. Libya began privatising the pharmaceutical system in 2003. Pharmaceutical supplies were previously provided to both the public and private sectors by the National Pharmaceutical and Medical Supplies Company, but drug companies are also permitted to market and supply their products to both public and private health sectors through local agencies. In 2009, over 300 international pharmaceutical manufacturers from Europe, Asia and the Middle East were registered as permitted drug suppliers for Libya 17 .In Libya,the quality of drug information of pharmaceutical advertisements is largely unreported. Hence, the aim of this study is to examine patterns of promoted products in pharmaceutical brochures and to evaluate the rationality of drug advertisements in the pharmaceutical brochures by using the WHO guidelines for ethical drug promotion. The study also investigates the prevalence of persuasive techniques and the quality of the cited references in these materials.
METHODOLOGY:
The design of this study was based on WHO Ethical Criteria for Medicinal Drug Promotion and other principles from previous studies 12, 18, 19 .Brochures were[ [collected from doctors' offices in primary and secondary healthcare institutes in three cities in Libya (Tripoli, Benghazi and Sebha). As a convenience sample, three hundred brochures were collected between August and December 2010. Brochures were sorted to exclude: 1) Monographs A 2) Reminder brochures with only the name of the product and no risk information or suggestions for use 3) Promotional material for medicinal devices and equipment 4) Pamphlets heightening awareness of particular diseases without mentioning pharmacotherapy 5) Advertisements for cosmetic products. Duplicates were removed while brochures with different advertisements for the same drug were included. Promoted products were categorised according to therapeuticclasses and their formulation. We examined all the elements of the bro chures and assessed their compliance with the WHO criteria for drug advertisements 19 , Table1a.Citation referencesobtained for assessment were retrieved from Pub Med, the University of South Australia's database or Google search engine. In each piece of advertising, the whole of the written text, photos and graphs and any surrounding material were checked against the criteria for evaluating citations, references, text, graphical information and pictorial persuasive techniques in, Tables1b and1c. We used descriptive statistics for statistical analysis. All values were expressed as frequencies and percentagesin graphs andtables.
RESULTS:
Characteristics of promoted products Of 300 collected brochures, 190 promotional materials were evaluated for 132 non-proprietary products(Appendix1). Outof these190 brochures, (n=22; 11.5%)of advertise ments were combination fixed dose products "multiple active ingredients" compared to168 (88.4%) were single active ingredients the majority of promoted products (n=153; 80.5%) were oral products while external use and parenteral products were (n=18; 9.5%) for each. Of 132 products identified by a generic name, only Table 1b . Criteria for evaluation of references supporting claims in pharmaceutical brochures Type of reference (journal article, abstract, books, data on file, government documents, websites, etc.). Containing all of the information necessary to identify references. A citation was considered complete if it included, at a minimum, author(s) name, title, publisher, year of publication and volume regardless of the format styles. Whether the cited references were retrievable vs. non-retrievable. (Retrievable if soft copy is obtained from the above resources in the internet and non-retrievable if the reference is not available or data on file). Whether the study or authors were affiliated with the pharmaceutical industry. Table 1c . Criteria for analysing presentation styles and persuasion techniques in the textual and pictorial part of promotional brochures. 
(19% areon theWHO [[ Essential Medicines list (2011)
. The largest category of drug was antibiotics (n=52; 27.3%), Table2. The most frequently promoted were amoxicillin/clavulanic acid (n=9) and clarithromycin (n=7), Appendix 1. The second major category of promoted products was cardiovascular (CV) drugs (n=39; 20.5%). Over the half of these drugs were antihypertensive agents (n=23; 58.9%), and angiotensin receptor blockers (ARBs) products (n=9) were the most frequent. Other well-promoted antihypertensive drugs were Amlodipine (n=4) and Valsartan (n=3). Statins made up (23%) of the CV products and atorvastatin appeared five times. Antithrombotic agents made (17.9%) of the CVs drugs and clopidogrel appeared four times. Twenty seven products (14.2%) were gastrointestinal agents (GITs) and PPIs represent 10 products from these GITs. Non-steroidal antiinflammatory drugs (NSAIDs) comprised nearly 10% of total promoted products (n=17; 8.9%). Diclofenac was the most promoted product in this category (n=4) and there was one advertisement for a COX-2 selective inhibitor, Etoricoxib. Oral hypoglycaemic drugs (n=11) were approximately six per cent (5.7%) of the total. Glimepiride was found five times (4 times as a single product) and metformin four times (only once as a single active ingredient). Classification of promoted products is presented in, Table 2 . 
Persuasive techniques used in brochures:
Graphical presentations were displayed in (n=114; 60%) of promotional brochures. Of 190 surveyed brochures, only (n=4; 2.3%) of the advertisements displayed the generic name as prominently as the brand name. The majority of the 190 (n=136; 71.5%) used only the trade name instead of the general name in the context of prescribing information section, Table 4 .The majority of prescribing information (n=118; 62%) appeared in a font size less than the main body text, and almost a half of brochures(49.4%) used a font size less than eight point. One in eight (n=24; 12.6%) dropped to six points or below (Arial font readability equivalent).The majority of printed materials had pictorial information "pictures" (n=183; 96.3%) and emotional statements (n=169; 88.9. %), Table4. Most pictures showed the promoted products (n=150, 78.9%) and a large proportion of also showed the patient or end user of the products (n=76; 40%). Less frequently, pictures focused on the site of drug action (n=26; 13.7 %). There were also a few brochures with other illustrations such as cartoons, landscapes or animals. 
DISCUSSION:
As far as we know, this is the first study in Libya to focus on quantitative aspects of the information and persuasive content in pharmaceutical brochures circulated to doctors' offices by PCRs. The different categories of drugs in the pharmaceutical brochures in this study provided an insight into the marketing of drugs in Libya. The majority of promoted drugs (80.5 %) were oral dosage form and a minority (9.5% each) for external and parenteral use. A similar trend was reported in a study in Zimbabwe 12 in which oral dosage products accounted for 61% of the total advertising, followed by parenteral preparations (22%) and topical preparations with only 4%. This trend is not unexpected since the oral route, in general, is the most convenient and usually the safest and least expensive for the patient. For rational drug use essential drugs must be available 21 . All of the promoted products in these brochures are produced by foreign manufacturers. The study found that only 25 items from 132 promoted products consistent with the WHO's list of essential medicines. The Libyan Health Law, act number 106 of 1973 and its explanatory notes of 1975, states that registration of medicines with the Libyan Ministry of Health should precede the availability of any medicine in the Libyan market. Since all the promoted drugs assumed to be approved by the ministry of health, one may raise question as to whether these products cover the essential drugs needed in Libya. Full discussion about the selection process of the list of essential medicines is beyond the scope of this paper. The study revealed that anti-infective agents had the highest rate of promotion (27%), particularly the three classes: B-lactams, macrolides and quinolones. Amoxicillin/clavulanic acid, and clarithromycin antibiotic were the most frequently promoted products of all. This promotion of antibiotics is consistent with the trend of drug prescriptions in Libya. A previous study reviewed 700 prescriptions from Tripoli and Alzawiya and found 25% of prescribed medicines were antibiotics 22 . Another retrospective drug utilization study in different wards of Zawiya TeachingHospital 23 found that amoxicillin/clavulanic was the most-used antibiotic in two consecutive years, 2008 and 2009.The current study did not assess the relationship between the written information provided by the PCRs and doctors' prescribing behaviour. However, Zoutman, et al. 24 assessed antibiotic prescribing for upper respiratory tract infections (URTIs) by family doctors and the subsequent influences on antibiotic prescribing and found that doctors who relied on commercial information sources, such as PCRs, were more likely not to prescribe first line antibiotics for acute sinusitis. The current study found that broad spectrum antibiotics were more frequently promoted than narrow products. In Libya, there are no national therapeutic guidelines or policy for rational prescribing of antibiotics. Overuseof antibiotics,particularlybroad-spectrum antibiotics, in primary care is a major contributing factor to increased prevalence of resistant pathogens in the community 25 .Of the cardiovascular medications (n=39; 20.5%), antihypertensives were the most promoted subclass (n=23; 58.9%), and ARBs were the more frequently advertised (n=9) than other antihypertensives. Consistently, the increased use of gastrointestinal drugs was driven by increased advertising of PPIs. We found that PCRs are more likely to promote new generation products like broad spectrum antibiotics, anticoagulants,antihypertensives, statins,andPPIs, thanexisting drugs. Doctors' choices of drugs are influenced by perceived pharmacological advantages and cost effectiveness over the alternatives. Newer drugs sometimes offer improvements over existing therapies. However, a study in Canada 26 assessed 1147 new products showed that only 142 (12.3%) were the drug of choice to treat effectively a particular illness or to provide a substantial improvement over existing drugs. Previous studies 27, 28 reported that claims about new drugs may be inaccurate or biased and may encourage usage of more expensive branded drugs. Recently (2012), the United States Justice Department fined the GlaxoSmithKline (GSK) company $US 3 billion for unlawfully promoting unauthorized uses "off-label use" of paroxetine and bupropion, and for failing to report safety data about the controversial GSK diabetes drug rosiglitazone. The aggressive promotion of new drugs suggests that the new drugs are superior to existing products despite doubts in the literature about their actual value 29 . Prescribing new and expensive drugs because of pharmaceutical marketing is the main reason for rising prescription expenditures. The effectiveness of drug detailing is directly dependent on the quality of drug information provided and this will have a direct effect, positively or negatively, on doctors prescribing decisions. Rational prescribing assumes that a medical professional balances the positive and negative features of each product and considers all the alternatives. Brochures should contain all relevant and pertinent scientific information. In this study, almost all brochures fail to comply with the WHO Ethical Criteria for Medicinal Drug Promotion. They provide unbalanced information about their products. Information regarding indication, dosage regimen and pharmacological properties was satisfactory in most cases (>90%). However, safety information which may discourage use of a drug was less frequently presented. The risk information (contraindications, pregnancy and lactation information, precautions, adverse effects and major interactions) were reported in average 67.7% of the promoted literatures. This finding matches another study conducted in Libya in (2010) in which 41 -65% of the medical practitioners surveyed reported that PCRs rarely or never mentioned safety information 30 . To omit safety information can negatively impact on rational drug prescribing decision and patient healthcare outcome. In this study, 30% of brochures (n=56) did not contain any reference to support the claims. Similar finding were also observed in other studies 31, 33 .Pharmaceutical companies provide bibliographical references in brochures of promoted products to give[ apparent respectability and credibility to the advertisements.However,the quality of these references varies widely and some are not readily accessible. A systematic review study by Othman et al. 34 found that citation errors are widespread in pharmaceutical company advertisements worldwide. This study found that nearly one third (32.6%) of the total references (n=750) could not be retrieved. Further analysis revealed that the majority of non retrievable references (n=158; 65%) contained only partial bibliographic information, compared to 16.3% (n=40) completely formatted. Also a considerable number came from private sources such as industrial data on file (n=33; 13.5%), which is in most cases not available from pharmaceutical companies when it is requested 31, 35 .It is also noteworthy that presenting a citation does not mean that the claims in advertisements are valid. Lankinen et al. 36 found in that all of unambiguous claims by pharmaceutical companies did not cited with strong scientific evidence but they had relatively more supporting references than other claims. Therefore, regardless of the claims in an advertisement, high-quality citations are crucial for credibility, and if the cited reference is nonretrievable, the information is unreliable. Full bibliographic information enables health professionals to check validity of the claims in the brochures. In this study, the majority of references of journal researches 218 (61.4%) involved work sponsored by or authors affiliated to pharmaceutical companies compare the figure of 58 % from Cooper et al 31 . In a systematic review 37 , 16 studies assessed the relationship between the outcome and source of funding. This review found that 13 studies revealed the existence of relationship between funding by pharmaceutical industries and the trial outcomes in favour of their funded products. Funding predicates bias, one might say. Another two studies 35, 38 found the majority of pharmaceutical advertisements to be based on studies of poor methodological quality. Therefore, concerns about brochures are well established. The current study found that graphical data appeared in nearly two thirds of the surveyed brochures (n=114; 60%). Remarkably, this percentage is quite high compared to another study done in India which found only 15.9% had graphs 39 . The visual approach communicates information summarises outcomes and simplifies the content of the advertisement. However, these graphs also may misrepresent data, leading to wrong inferences and incorrect conclusions. Cooper et al. found that of 74 graphs in medical journals, 8% had errors, 5% were visually confusing and 12% did not follow standard graphing techniques. Another study 40 reported that necessary information such as confidence interval of p value, power calculations and "number needed to treat" were often missed in pharmaceutical advertisements. It is important to note that the compliance of the content of pharmaceutical brochures for WHO essential criteria does not guarantee the safety or the effectiveness of promoted products. Since doctors are busy professionals, they may have little capacity to process abundance of advertising messages and editorial content. Under such circumstances, brand awareness, knowledge, and images affect doctors' cognitive beliefs leads to sympathy for the brand and brand preference, which in turn affects prescribing habits 41 .The way information is presented can greatly affect the cognitive activity of audience receiving it. Brochures incorporate various psychological and emotional techniques to persuade the reader. The primary purpose of drug advertisements is to create product awareness, attract attention, arouse interest, create positive attitudes, and influence prescribing decision. The persuasive aspects of both visual and text elements characterised most of the brochures. In advertising techniques, the font sizes, pictorials, headlines and body text of the brochures all have specific marketing influence. Hence, the level of understanding and comprehension of the advertisement are prerequisite into the consumer memory and change their attitude 42 . Consequently, clear writing captures the reader's attention and legible text is essential for speed and comprehension 43 . This study found that product-favouring information, such as trade name, pharmacological efficacy and emotional words and phrases about uniqueness, were presented in text with larger font size than generic drug names or the prescribing information sheets. Headlines draw attention and increase the persuasive connection with the brand name. A prominent brand name is easily to recall and retrievable while writing a prescription than general name. However, the smaller font size used for generic information distracts attention from it and affects the capability of the information sheet to be comprehended properly. The decision making process can be influenced by retrieval of brand information from memory and this knowledge can be acquired from sources in the external environment. Busy practicing physicians are more likely to extract the information quickly and indistinct print decreases the interaction of readers with it. Advertising research confirms that frequent exposure to advertisements increases brand awareness 44, 45 . Over the half of brochures use the trade names instead of general name in the prescribing information sections. In the same way as with the font size, improving the memory of the brand name of the promoted product increases the chance of this brand name being prescribed by the doctor.
Using branded drugs instead of generics is one of the reasons for rising prescription expenditures 46 . Steinman et al. 47 examined the frequency of physicians using brand or generic terminology for prescription medications. They found 79% of prescriptions used brand names and had a generic equivalent at the time of the survey. In Libya a study 22 found only 10% of medicines were prescribed by generic name. This lower rate in Libya may be attributed to the influence of the interaction of prescribers with PCRs. On the other hand, this could be also attributed to money spent on brand-name promotion. In the United States, the FDA recommends that generic name should have a prominence equal to that of the brand name including all printing features. If the running text spans more than one page, it also recommends that the established name accompany the generic name at least once per page 48 .Physicians want medicines to be safe, effective, tolerated, and acceptable to patients. Advertisements use several means such as pictures or emotive words to associate the brand name with these features. Pharmaceutical companies use a unique brand identity to differentiate their products from the competition and also use emotional phrases or pictures subliminally to stimulate the cognitive process 49 . We found visual images (89%) or emotional texts (87.3%) in almost all of the brochures. All these marketing aspects are designed to work together to persuade physicians to prescribe a promoted product. In other words, repetition of the same message in different ways augments the value of the original message .Pictures provide motivation for readers to read and comprehend the brochures 49 . They are more understandable and more readily absorbed than similar message presented only in words since the pictures likely activate a visual as well as a verbal encoding process 50 . Pictures also create a positive attitude and more cognitive elaboration through emotional affects and the reinforcement of verbal text 51 . For instance, pictures of the promoted products (78% of total brochures) make implicit a set of unique associations with brand name and company product which are easily coded in the visual memory of the prescriber and which may take a longer time to deteriorate from the brain than text messages do. Similarly, pictures that imply superior patient healthcare outcome were found frequently in brochures (40%of total brochures). These emotional affects in advertisements are comprehensive, memorable and influential and divert the prescribers from a merely medical context to a socioculturalperspective 52 . Less frequently, brochures have informational pictures such as the mechanism or site of drug actions (n=26; 14%).There are several implications that can be derived from this research. The quality of information provided during drug detailing visits has repercussions for adopting or not adopting a particular drug 30 . In many developing countries, rational prescribing guidelines are either unavailable or not effectively implemented and PCRs are frequently the only source of drug information 53 . In absence of an independent source of drug information, as in Libya, commercial information tends to replace retrieval based evidence. Earlier studies reported that PCR interactions with doctors can have a negative impact on prescribing practice 54 . Our findings highlight the current state of pharmaceutical promotion in Libya and offer policy makers insight into areas for improvement. To ensure balanced information and consistent standards about promoted products needs a continuous process of monitoring, evaluation and appraisal of pharmaceutical advertisements by the health professional disciplines. Omitting specific requirements of information sheets such Most pharmaceutical brochures use emotional claims in promoting company products to reinforcetheir persuasive messages. Unethical pharmaceutical promotion and low quality of drug information lead to irrational prescribing of drugs. Physicians may underestimate or be unaware of hidden messages in images and emotional texts in advertisements, which can create a positive attitude toward promoted products. Physicians need to assess carefully the emotional statements and images in drug promotional literature before making any decisions based on them. Government and national medical agencies should also take practical positions in monitoring pharmaceutical promotion activities to ensure consistent standards and appropriate control of drug advertisements. Another problem that needs specific attention is that the Libyan regulations for pharmaceutical promotion urgently need to be reformed and updated, consistent with recent developments in pharmaceutical drug marketing. All drug advertising should include risk information and provide complete scientific evidence in citations that (a) actually support the claims and (b) can actually be retrieved. Claims should be balanced and factual without emotional information.
LIST OF ABBREVIATIONS:

CONCLUSION:
The common promoted products are antibiotics, cardiovascular drugs and PPIs. Almost all the circulated brochures of PCRs did not provide essential information recommended by WHO ethical criteria for medicinal drug promotion, with widespread citation errors in bibliographic references. The majority of pharmaceutical brochures employ persuasive techniques in their marketing, designed to be memorable and influential.Pharmaceutical companies should closely scrutinise their printed advertisements to ensure their content complies with international standards. Since the assessment of the rationality of promotional materials requires scientific skills, we support the idea that health professionals should be educated about critical appraisal and evaluation of evidence. This may also teach health professionals about marketing techniques and help them to attend more closely to visual presentations and to analyse them more critically.
Limitations: There are limitations to this study. The validity of the study results may be limited by the number of pharmaceutical brochures surveyed. The generality of our results is uncertain because we focused only on advertisements in Libya in 2010. The aim of this study was not to directly and objectively assess the accuracy and efficacy of the information provided by PCRs. We did not assess whether the references adequately substantiated each claim made in the advertisements. We did not attempt to request data on file from pharmaceutical companies. Although we investigated all journal advertisements in the database of the University of South Australia, this may not reflect the content of other databases or other types of electronic libraries. Hence, the use of a single database to assess the retrievability of references could be also considered a potential limitation.
